1. Market Research
  2. > Pharmaceutical Market Trends
Non-Alcoholic Steatohepatitis Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Product, Application, and Sales Channel

Non-Alcoholic Steatohepatitis Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Product, Application, and Sales Channel

  • April 2022
  • 178 pages
  • ID: 6279452
  • Format: PDF
  • The Insight Partners

Summary

Table of Contents

Search Inside

The non-alcoholic steatohepatitis (NASH) market is projected to reach US$ 24,266.81 million by 2028 from US$ 1,631.92 million in 2021; it is expected to grow at a CAGR of 47.1% from 2021 to 2028.

Major factors driving the non-alcoholic steatohepatitis (NASH) market growth include the rising prevalence of NASH and increasing initiatives for the awareness of NASH.The growing number of clinical trials involving combination studies of drugs are likely to introduce future trends in the market during the forecast period.

However, the lack of established guidelines for the diagnosis and management of NASH, and withdrawal of drugs from the marketing authorization stage of clinical trials hamper the non-alcoholic steatohepatitis (NASH) market growth.

NASH is a potentially fatal illness that causes extensive scarring and cirrhosis of the liver.NAFLD is the most common chronic liver disease globally.

NASH is a progressive form of NAFLD, which is gradually becoming the major cause of end-stage liver diseases and liver transplantation.According to the data published by the Global Liver Institute, NASH was termed as an epidemic on June 12, 2019.

It affects over ~115 million people, and 357 million people are expected to be affected by this condition by 2030.Obesity, type 2 diabetes, and hyperlipidemia are substantial risk factors for NAFLD and NASH; more than ~70% of people are obese, ~75% have type 2 diabetes, and 20–80% have hyperlipidemia worldwide.

NASH, if left untreated, can progress to cirrhosis and liver cancer, and raise the need for a liver transplant.

As per the data published by the American Liver Foundation, NAFLD is the most common chronic liver disease in the US. ~25% of adults in the US have been estimated to have NAFLD, of which ~20% have NASH, i.e., 5% of adults in the US. According to the NASH Education Program, NASH prevalence is expected to increase by 63% from 2015 to 2030 and NASH is predicted to become the major cause of liver transplantation in the US during 2020–2025. The American Association for the Study of Liver Diseases published a report in 2018 using Markov modeling to forecast NAFLD disease till 2030. As per the study, the prevalence of NAFLD and NASH cases is expected to increase by 21% and 63%, respectively, resulting in 33.5% and 27% prevalence rates, respectively, in adults.

Despite its increasing prevalence, NAFLD/NASH remains an under-recognized condition, and early detection is critical to reducing the risk of progression and its associated consequences. Thus, the growing prevalence of NASH drives the non-alcoholic steatohepatitis (NASH) market.

The non-alcoholic steatohepatitis (NASH) market, by product, is segmented into vitamin E and pioglitazone, ocaliva, elafibranor, selonsertib & cenicriviroc, and others.In 2021, the others segment held the largest share of the market.

The selonsertib & cenicriviroc segment is expected to register the fastest CAGR in the non-alcoholic steatohepatitis (NASH) market during the forecast period.

The non-alcoholic steatohepatitis (NASH) market, based on application, is segmented into treatment and diagnosis.In 2021, the treatment segment held a larger share of the market.

However, the treatment segment is expected to register a higher CAGR during the forecast period.

The non-alcoholic steatohepatitis (NASH) market, based on distribution channel, is segmented into hospital pharmacy, retail pharmacy, and online provider.In 2021, the retail pharmacies segment held the largest share of the market.

Moreover, it is expected to register the highest CAGR in the non-alcoholic steatohepatitis (NASH) market during 2021–2028.

The Organization for Economic Co-operation and Development (OECD), National Institutes of Health (NIH), National Healthcare Service (NHS), Centers for Disease Control and Prevention (CDC), Diabetes UK, National Center for Biotechnology Information (NCBI), Korean Diabetes Association (KDA), United Nations (UN) Global Population Prospects, National Statistics Institute, and World Health Organization (WHO) are among the major secondary sources referred to while preparing the report on the non-alcoholic steatohepatitis (NASH) market.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Grace helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at [email protected] to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - [email protected] or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • $ 3500
  • April 2022
  • 152 pages

Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Bromodomain Containing ...

  • World
  • Cancer
  • Pharmaceutical
  • Industry analysis
  • Drug Approval
  • Prescription Drug Sales

ref:plp2022

Reportlinker.com © Copyright 2022. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on